Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
- 31 August 2001
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 37 (12), 1510-1513
- https://doi.org/10.1016/s0959-8049(01)00155-1
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Aromatase inhibitors and their use in the sequential setting.Endocrine-Related Cancer, 1999
- Status of aromatase inhibitors in relation to other breast cancer treatment modalities.Endocrine-Related Cancer, 1999
- Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinomaCancer, 1999
- Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnnals of Oncology, 1998
- Mechanisms of action of endocrine treatment in breast cancerCritical Reviews in Oncology/Hematology, 1995
- Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancerCancer, 1995
- Aromatease, its inhibitors and their use in breast cancer treatmentPharmacology & Therapeutics, 1993
- Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjectsJournal of Clinical Endocrinology & Metabolism, 1993
- The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Endocrine Treatment of Breast Cancer in WomenEndocrine Reviews, 1990